The Effect of Trim5 Polymorphisms on the Clinical Course of HIV-1 Infection by van Manen, Daniëlle et al.
The Effect of Trim5 Polymorphisms
on the Clinical Course of HIV-1 Infection
Danie ¨lle van Manen
1,2¤, Maarten A. N. Rits
1,2¤, Corrine Beugeling
1,2, Karel van Dort
1,2¤, Hanneke Schuitemaker
1,2,3,
Neeltje A. Kootstra
1,2¤*
1 Department of Clinical Viro Immunology, Sanquin Research, Landsteiner Laboratory, University of Amsterdam, Amsterdam, The Netherlands, 2 Center of Infection and
Immunity Amsterdam (CINIMA), University of Amsterdam, Amsterdam, The Netherlands, 3 Department of Experimental Immunology, Amsterdam Medical Center,
Amsterdam, The Netherlands
The antiviral factor tripartite interaction motif 5a (Trim5a) restricts a broad range of retroviruses in a species-specific
manner. Although human Trim5a is unable to block HIV-1 infection in human cells, a modest inhibition of HIV-1
replication has been reported. Recently two polymorphisms in the Trim5 gene (H43Y and R136Q) were shown to affect
the antiviral activity of Trim5a in vitro. In this study, participants of the Amsterdam Cohort studies were screened for
polymorphisms at amino acid residue 43 and 136 of the Trim5 gene, and the potential effects of these polymorphisms on
the clinical course of HIV-1 infection were analyzed. In agreement with the reported decreased antiviral activity of Trim5a
that contains a Y at amino acid residue 43 in vitro, an accelerated disease progression was observed for individuals who
were homozygous for the 43Y genotype as compared to individuals who were heterozygous or homozygous for the 43H
genotype. A protective effect of the 136Q genotype was observed but only after the emergence of CXCR4-using (X4) HIV-
1 variants and when a viral load of 10
4.5 copies per ml plasma was used as an endpoint in survival analysis. Interestingly,
naive CD4 T cells, which are selectively targeted by X4 HIV-1, revealed a significantly higher expression of Trim5a than
memory CD4 T cells. In addition, we observed that the 136Q allele in combination with the 2GG genotype in the 59UTR
was associated with an accelerated disease progression. Thus, polymorphisms in the Trim5 gene may influence the
clinical course of HIV-1 infection also underscoring the antiviral effect of Trim5a on HIV-1 in vivo.
Citation: van Manen D, Rits MAN, Beugeling C, van Dort K, Schuitemaker H, et al. (2008) The effect of Trim5 polymorphisms on the clinical course of HIV-1 infection. PLoS
Pathog 4(2): e18. doi:10.1371/journal.ppat.0040018
Introduction
The susceptibility to HIV-1 infection and subsequent
disease progression is highly variable between individuals.
Host genetic variations have previously been demonstrated to
account for at least part of these differences. Polymorphisms
in chemokine receptors that serve as HIV-1 coreceptors, or in
their natural ligands, have been associated with reduced
susceptibility to infection as well as disease progression [1–4].
Furthermore, certain HLA types have been correlated with
the clinical course of infection [5–8].
Variations in genes involved in innate immunity may also
contribute to the differential susceptibility of humans to
HIV-1 infection and the highly variable outcome of the
disease. Recently, the tripartite interaction motif 5a (Trim5a)
has been identiﬁed as part of the intrinsic immunity that
protects human and non-human primates against retroviral
infection [9,10]. Trim5a targets the capsid of the incoming
retrovirus in the cytoplasm directly after entry and interferes
with viral replication at an early post-entry step most likely at
the poorly understood uncoating process [11–19]. Species-
speciﬁc variations in Trim5a account for the restriction
pattern of speciﬁc retroviruses [20–26]. For example, HIV-1
replication is blocked efﬁciently by Trim5a of rhesus
macaques and African green monkeys, whereas SIV-mac is
only restricted by Trim5a from African green monkey.
Human Trim5a efﬁciently blocks N-tropic MLV and equine
infectious anaemia virus, but is much less efﬁcient in
restricting HIV-1 replication. This indicates that HIV-1 has
at least partially adapted to the human variant of this
restriction factor. Recently, we observed that Trim5a escape
variants developed late in infection in a proportion of the
HIV-1 infected individuals [27]. The emergence of the escape
variants was preceded by a prolonged asymptomatic phase,
indicating that Trim5a mediated suppression of viral
replication indeed plays a role in HIV-1 pathogenesis.
The potential role of polymorphisms within the Trim5 gene
on HIV-1 susceptibility has recently been studied [28–31]. Of
the eight nonsynonymous polymorphisms that have been
identiﬁed in the Trim5 gene, two have been reported to have
functional consequences with regard to the antiviral activity
of Trim5a (H43Y and R136Q) [28,30]. The H43Y is located in
the RING domain of Trim5a and may impair its putative E3
ligase activity [28,30]. Indeed, the 43Y variant of Trim5a was
less efﬁcient in restricting HIV-1 replication in vitro [28,30].
The R136Q polymorphism has been associated with a slightly
higher anti-HIV-1 activity of Trim5a [30]. In agreement, the
R136Q polymorphism was more frequently observed in high
risk seronegative as compared to HIV-1 infected individuals
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conﬁrmed in other study populations [29,30]. So far no
signiﬁcant association between Trim5 polymorphisms and
HIV-1 disease progression have been demonstrated [29,31,32].
Here we studied the effect of the Trim5a H43Y and R136Q
polymorphisms on the clinical course of HIV-1 infection in
participants of the Amsterdam Cohort studies. In addition,
we analyzed whether the R136Q genotype in combination
with a SNP in the 59UTR of Trim5 ( 2G/C) was associated with
susceptibility to HIV-1 infection or disease progression.
Results
Distribution of H43Y and R136Q Trim5 Genotypes
The prevalence of Trim5a polymorphisms H43Y and
R136Q was studied in 327 HIV-1 positive participants of
the Amsterdam Cohort studies. For the H43Y polymorphism
a minor allele frequency of 0.115 was observed. Of the 327
HIV-1 positive participants, 61 (18.7%) were heterozygous
and 7 (2.1%) were homozygous for the 43Y allele. The R136Q
polymorphism was observed at a minor allele frequency of
0.379. Of the 327 participants, 156 (47.7%) were heterozygous
and 46 (14.1%) were homozygous for the 136Q allele. Six
mutually exclusive haplotypes were observed for the combi-
nation of R136Q and H43Y polymorphisms: 43HH/136RR (n
¼ 88), 43HH/136RQ (n ¼ 125), 43HH/136QQ (n ¼ 46), 43HY/
136RQ (n¼31), 43HY/136RR (n¼30) and 43YY/136RR (n¼7).
The 43Y polymorphism was not observed in the group
homozygous for the 136QQ genotype and the 136Q poly-
morphism was never observed in combination with a
homozygous 43YY genotype, also conﬁrming that the 43Y
polymorphism and the 136Q polymorphism are not located
on the same allele [29,31]. No signiﬁcant differences in the
H43Y or R136Q minor allele frequencies were observed
between the HIV-1 seropositive individuals and healthy
controls (allele frequencies of 0.106 and 0.389 for H43Y and
R136Q, respectively).
Effect of the H43Y Trim5 Genotype on the Clinical Course
of HIV-1 Infection
Kaplan Meier and Cox Proportional Hazard analysis with
clinical AIDS (Deﬁnition CDC 1987 and 1993), CD4 T cell
counts below 200 cells/ll blood, and plasma viral RNA load
above 10
4.5 copies per ml plasma were used as end points to
determine the effect of polymorphisms in the Trim5 gene on
disease progression. We observed an accelerated disease
progression in the group homozygous for the 43Y allele
relative to the 43 HH wild type genotype, with a relative hazard
(RH) of 3.1 (p ¼ 0.006) and 2.8 (p ¼ 0.007) for AIDS diagnosis
according to the 1987 or 1993 CDC deﬁnition, respectively
(Figure 1A and 1B; Table 1). An accelerated progression rate
was also observed when CD4 T cell counts below 200 cells per
ll blood were used as end point (Figure 1C; Table 1). The
median viral RNA load of participants of the Amsterdam
cohort progressing to AIDS has previously been determined at
10
4.5 copies HIV-1 RNA per ml plasma [1]. When viral RNA
load above 10
4.5 copies per ml plasma was used as endpoint in
the survival analysis, we again observed an accelerated disease
progression for individuals homozygous for the 43Y genotype
(Figure 1D; Table 1). The heterozygous genotype (43HY) was
not associated with delayed disease progression (Figure 1).
Development of CXCR4 using HIV-1 variants (X4-variants)
has previously been associated with an accelerated disease
progression [33]. The ability of HIV-1 variants to use CXCR4
as a coreceptor and replicate in MT2 cells was analyzed
routinely during follow-up in the cohort studies in 319 of 327
individuals from our study population. During the course of
infection X4-variants developed in 126 individuals. No
association between the prevalence of X4-variants and the
H43Y genotype could be observed (data not shown). However,
X4-variants did develop more rapidly in individuals who were
homozygous for the 43Y genotype (Figure 1E; Table 1).
Our study population consisted of 130 participants who
seroconverted for HIV-1 antibodies during follow-up and 197
seroprevalent participants with an imputed seroconversion
date [34]. Inclusion of seroprevalent participants in our
analysis did not bias our data and Cox regression analysis
stratifying for seroconvertors and seroprevalent participants
gave similar results (data not shown).
Effect of the R136Q Trim5 Genotype on the Clinical Course
of HIV-1 Infection
Next we examined a potential role for the R136Q
polymorphism in Trim5 on the clinical course of HIV-1
infection. Using clinical AIDS (Deﬁnition CDC 1987 and
1993), CD4 T cell counts below 200 cells/ll blood or viral RNA
load above 10
4.5 copies per ml plasma as endpoint in Kaplan
Meier and Cox proportional hazard analysis, no signiﬁcant
associations between the 136RQ or 136QQ genotype and the
clinical course of infection were revealed (data not shown).
The R136Q polymorphism also had no effect on the time to
ﬁrst detection of X4-variants (data not shown). In addition,
the prevalence of CXCR4 using HIV-1 variants was not
associated with the R136Q genotype.
Next we analyzed whether a potential effect of the R136Q
Trim5 genotype was dependent on the coreceptor usage of
the virus present. The R136Q genotype had no signiﬁcant
effect on the clinical course of infection when only CCR5
using HIV-1 variants (R5-variants) were present irrespective
the end point used in the survival analysis (data not shown).
However, a signiﬁcant protective effect on disease progres-
sion associated with the R136Q genotype was observed after
X4-variant development using the median viral RNA load of
participants of the Amsterdam cohort progressing to AIDS
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Author Summary
The clinical course of HIV-1 infection is highly variable between
individuals, and host genetic variations may at least account for part
of these differences. Recently two single nucleotide polymorphisms
in the tripartite interaction motif 5 gene (Trim5) have been reported
to affect the antiviral activity of the Trim5a protein. Here we
analyzed the effect of these polymorphisms on the clinical course of
HIV-1 infection in participants of the Amsterdam Cohort studies. We
observed an accelerated disease progression for individuals who
were homozygous for the 43Y genotype that has been associated
with a decreased antiviral activity of Trim5a in vitro. The 136Q
genotype has in vitro been associated with a slightly higher anti-HIV-
1 activity. We observed a protective effect of the 136Q genotype
only after the emergence of CXCR4-using HIV-1 variants using viral
load above 10
4.5 copies per ml plasma as an endpoint in survival
analysis. These results suggest that genetic variations in the Trim5
gene may influence the clinical course of HIV-1 infection and
confirm a role of Trim5a on HIV-1 in vivo.(10
4.5 copies per ml) as an end point in survival analysis, with
a RH of 0.44 (p ¼ 0.008) and 0.26 (p ¼ 0.030) for the
heterozygous 136RQ and homozygous 136QQ genotype,
respectively as compared to the 136RR genotype (Figure 2;
Table 2). At the moment of X4-development the viral load of
individuals who were homozygous (QQ), heterozygous (RQ)
or wild type (RR) for the amino acid residue at position 136
was similar (data not shown). The R136Q polymorphism was
not associated with disease progression after X4-variant
development using clinical AIDS or CD4 cell counts below
200 cells ll blood as end points (Table 2).
Trim5a mRNA Expression Levels in Naı ¨ve and Memory
CD4 T Cells
The protective effect of the 136Q Trim5a variant on
disease progression only after emergence of X4 variants may
imply that Trim5a has a stronger effect on X4 variants than
on R5 variants. Previously we demonstrated that R5 and X4
HIV-1 variants partially reside in different CD4 T cell
compartments due to differential expression of coreceptors
CCR5 and CXCR4 [35,36]. R5 variants were selectively
isolated from CD4 memory T cells, whereas X4 variants were
isolated from memory and naı ¨ve CD4 T cells. Here we
analyzed whether differences of the Trim5a mRNA levels in
naı ¨ve and memory CD4 T cell populations could contribute
to the differential effect of the 136Q variant on X4 and R5
variants in vivo. Naı ¨ve and memory CD4 T cells were isolated
from PBMC from 12 healthy controls by FACS sorting based
on CD45RO and CD27 expression and Trim5a mRNA levels
were analyzed by quantitative real time PCR. To correct for
differences in input, Trim5a mRNA levels were normalized
Figure 1. Survival Analysis for the H43Y Genotype
Kaplan Meier analysis for time in years from seroconversion to AIDS according to the CDC 1987 definition (A), to AIDS according to the CDC 1993
definition (B), to CD4 count below 200 cells/ll blood (C), to viral RNA load above 10
4.5 copies per ml plasma (D), and to first detection of X4-variants (E)
based on the H43Y genotype. Bold lines indicate individuals with the wild type genotype (43HH); dashed black lines indicate individuals heterozygous
for the 43Y genotype (43HY); thin black lines indicate individuals homozygous for the 43Y genotype (43YY).
doi:10.1371/journal.ppat.0040018.g001
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Trim5 Polymorphisms and HIV-1 Infectionfor b-actin mRNA levels. Trim5a mRNA levels were signiﬁ-
cantly higher in naı ¨ve (CD45RO CD27þ) CD4 T cells as
compared to memory (CD45ROþ) CD4 cells (p ¼ 0.019)
(Figure 3A).
In addition, Trim5a mRNA levels in naı ¨ve and memory
CD4 T cells were analyzed in HIV-1 positive individuals early
and late in the course of infection (23 PBMC samples from 11
individuals). Although no differences in Trim5a mRNA levels
were observed during the course of infection, we again
observed a signiﬁcantly higher Trim5a mRNA level in naı ¨ve
CD4 T cells as compared to memory CD4 T cells (p ¼ 0.003)
(Figure 3B).
Effect of Combined R136Q and  2G/C Genotypes on
Susceptibility to HIV-1 Infection and Disease Progression
Recently a G to C polymorphism at position  2 in the
59UTR of the Trim5 gene ( 2G/C; rs3824949) in combination
with the R136Q polymorphism has been associated with
enhanced susceptibility to HIV-1 infection (136Q/ 2G hap-
lotype) and accelerated disease progression (136R/ 2G
haplotype) [29]. To analyze whether the combined R136Q
and  2G/C genotype was also associated with HIV-1 suscept-
ibility or disease progression in our study population, we
genotyped our study population for the G to C polymorphism
at position  2(  2G/C). The  2C allele frequency was 0.486
and 0.418 in our HIV-1 positive individuals and healthy
controls, respectively. When the 2G/C genotype was analyzed
in combination with the R136Q genotype no signiﬁcant
differences in the distribution of the combined genotypes was
observed between the HIV-1 infected individuals and the
healthy controls. The  2GG genotype was not observed in
combination with the homozygous 136Q genotype in both
study populations.
Next we analyzed the effect of the combined R136Q and
 2G/C genotypes on disease progression using clinical AIDS
(Deﬁnition CDC 1993) as an end point. Individuals carrying
the 136Q allele (136RQ and 136QQ) in combination with the
 2GG genotype showed an accelerated progression to disease
in comparison to the 2GC (p¼0.009; RH 2.6; 95% CI 1.3–5.2)
and  2CC genotype (p ¼ 0.056; RH 2.1; 95% CI 1.0–4.3)
(Figure 4). In contrast to the study by Speelmon et al. [29], no
signiﬁcant effect of the  2G/C genotype on disease pro-
gression was observed in the group with the 136RR genotype.
AIDS Incidence in Relation to H43Y Genotype and Other
Progression Markers
Uni- and multivariate relative hazard analysis were used to
determine the predictive value of the Trim5 H43Y genotype
Table 1. Cox Regression Analysis for Progression to AIDS, CD4
Cells ,200 Cells/ll, and X4-Variant Development
Endpoint Number Event 43YY versus 43HH
p-Value RH (95% CI)
AIDS (CDC1987) 327 188 0.006 3.2 (1.4–7.3)
AIDS (CDC 1993) 325 215 0.007 2.8 (1.3–6.1)
CD4 ,200 cells/ll 325 182 0.001 3.7 (1.7–8.0)
X4-variant development
a 319 108
b 0.039 2.9 (1.1–8.0)
RNA load .0
4.5 copies/ml 324 214 0.036* 2.3 (1.1–4.8)
aX4-variants that develop before the start of active antiretroviral therapy are counted as
events.
bX4-variants emerged before the start of effective antiretroviral therapy in 108 out of 126
individuals who developed X4-variants.
*p-Value did not reach significance after Bonferroni correction (Simes-Hochberg method).
doi:10.1371/journal.ppat.0040018.t001
Table 2. Cox Regression Analysis for Progression to AIDS, CD4 Cells ,200 Cells/ll, or Viral RNA Load .10
4.5/ml after X4-Variant
Development
Endpoint Number Event 136RQ versus 136RR 136QQ versus 136RR
p-Value RH (95.0% CI) p-Value RH (95.0% CI)
AIDS (CDC1987) 114 75 0.146 0.7 (0.4–1.1) 0.329 0.7 (0.3–1.4)
AIDS (CDC 1993) 104 93 0.666 0.9 (0.6–1.4) 0.097 0.6 (0.3–1.1)
CD4 ,200 cells/ll 104 90 0.703 0.9 (0.6–1.4) 0.082 0.5 (0.3–1.1)
Viral RNA load .10
4.5/ml 70 46 0.008 0.4 (0.2–0.8) 0.030* 0.3 (0.1–0.9)
*p-Value did not reach significance after Bonferroni correction (Simes-Hochberg method).
doi:10.1371/journal.ppat.0040018.t002
Figure 2. Survival Analysis for R136Q Genotype after Emergence of X4-
Variants
Kaplan Meier analysis for time in years from the moment of first
detection of X4-variants to viral RNA load above 10
4.5 copies per ml
plasma based on the R136Q genotype. Bold black lines indicate
individuals with the wild type genotype (136RR); dashed black lines
indicate individuals heterozygous for the 136Q genotype (136RQ); thin
black lines indicate individuals homozygous for the 136Q genotype
(136QQ).
doi:10.1371/journal.ppat.0040018.g002
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Trim5 Polymorphisms and HIV-1 Infection(43YY) in combination with previously established prediction
markers such as CD4 T cell count, plasma viral RNA load, the
presence of X4-variants, and CCR5-genotype [1]. Univariate
analysis indicated that homozygosity for the H43Y poly-
morphism, CD4 T cell counts below 500 cells per ll, viral
RNA load above 10
4.5 copies per ml plasma and the presence
of X4-variants at 18–30 months after seroconversion were
predictive for more rapid progression to AIDS, whereas
heterozygosity for the CCR5-D32 genotype had a protective
effect (Table 3). Multivariate analysis at 2 years after
seroconversion indicated that CD4 T cell counts below 500
cells per ll blood, viral RNA load above 10
4.5 copies per ml
plasma, the presence of X4-variants and homozygosity for the
Trim5 H43Y genotype (43YY) were independent predictors
for progression to AIDS (Table 3). In our study population
the homozygous H43Y genotype was not observed in
combination with a heterozygous CCR5-D32 genotype ex-
cluding this parameter from the multivariate analysis.
Discussion
Old World monkey Trim5a very efﬁciently blocks HIV-1
infection at an early step in the viral replication cycle,
immediately after cellular entry. Human Trim5a is also able
to interfere with HIV-1 infection, albeit less efﬁciently.
Although this may suggest that HIV-1 has at least partially
adapted to human Trim5a, we have recently provided the
ﬁrst evidence that Trim5a might still play a role in HIV-1
pathogenesis [27]. We observed that HIV-1 variants contain-
ing a H87Q mutation in the cyclophilin A binding region of
capsid, which has previously been associated with escape from
Trim5a [11–16], developed during the late phase of infection
in a proportion of the HIV-1 infected individuals [27]. The
emergence of these Trim5a escape variants was preceded by a
prolonged asymptomatic phase implying that Trim5a con-
tributed to control of virus replication in vivo and concom-
itantly selected for Trim5a resistant variants.
Two genetic polymorphisms in the human Trim5 gene have
recently been described to affect the antiviral activity of
Trim5a on HIV-1. The H43Y polymorphism has been
associated with an impaired anti-HIV-1 activity of Trim5a
in vitro [28,30,32]. In agreement, we here observed that a 43YY
homozygous genotype was predictive for an accelerated
progression to AIDS, independent of CD4 cell counts, viral
RNA load in plasma, and HIV-1 coreceptor usage at 18–30
months after seroconversion.
In previous studies, the H43Y genotype had no effect on
HIV-1 disease progression [29–32]. Speelmon et al. observed
no signiﬁcant difference in viral RNA load in the period from
100 days until 2 years post infection between individuals who
were homozygous (YY), heterozygous (HY) or wild type (HH)
for amino acid residue 43 [29]. In agreement, we also did not
observe a difference in viral RNA load at 2 years after
seroconversion between the H43Y genotypic groups (data not
shown). However, the studies by Speelmon et al. and by
Goldschmidt et al. did also not show signiﬁcant differences in
CD4 cell decline between the H43Y genotypic groups [29,31].
Due to the low minor allele frequency for H43Y in the study
population by Speelmon et al., which had a size of only 90
Figure 3. Analysis of Trim5a mRNA Levels in Naı ¨ve and Memory CD4 T Cells
(A) Trim5a mRNA levels in naı ¨ve CD4 T cells (CD45RO-CD27þ) and memory CD4 T cells (CD45ROþ) obtained from healthy controls.
(B) Average Trim5a mRNA levels in naı ¨ve and memory CD4 T cells during the course of infection from HIV-1 infected individuals. Trim5a mRNA levels are
normalized for b-actin mRNA levels. Different symbols represent Trim5a mRNA levels of naı ¨ve and memory CD4 T cells from the different individuals.
doi:10.1371/journal.ppat.0040018.g003
Figure 4. Survival Analysis for the 2G/C Genotype in Combination with
the 136Q Genotype
Kaplan Meier analysis for time in years from seroconversion to AIDS
according to the CDC 1993 definition. Bold black lines indicate
individuals with the  2GG genotype; dashed black lines indicate
individuals with the 2GC genotype; thin black lines indicate individuals
with the  2CC genotype.
doi:10.1371/journal.ppat.0040018.g004
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43Y genotype might have been to low to observe signiﬁcant
difference between the genotypes. The discrepancy between
our results and those of Goldschmidt et al. may lie in their
relatively short average follow-up time of 3.2 years as
compared to the average follow-up of 7.9 years on patients
in our study. Nakayama et al. observed similar frequencies of
homozygous 43YY and heterozygous 43HY genotypes in
progressors and LTNP in a study population of Japanese
HIV-1 infected individuals [32]. In our Amsterdam cohort
however, none of the individuals homozygous for the 43YY
genotype had an asymptomatic follow up of 10 years or more.
Javanbakht et al. observed no signiﬁcant differences in
progression to CD4 T cell counts below 200 cells per ll
blood, AIDS deﬁning events or AIDS related deaths associ-
ated with the different H43Y genotypes in two large cohorts
of African Americans and European Americans [30]. In the
African American population the frequency of individuals
homozygous for the 43YY genotype is however very low which
might account for the discrepancy with our data. However,
the minor allele frequency for H43Y in the European
American cohort is similar to the frequency in the Amster-
dam cohort (0.114 and 0.115 respectively). Unfortunately, lack
of details on their European American cohort and their
analyses make it difﬁcult to bring up potential explanations
for the inconsistency in results.
The R136Q polymorphism has been associated with a slight
increase of the anti-HIV-1 activity of Trim5a in vitro [30],
although not conﬁrmed by others [28,29,31]. In agreement
with earlier reports [29,31], we did not observe an effect of
the R136Q polymorphism on disease progression. A protec-
tive effect of the 136Q variant was only evident in the phase
of infection when X4-variants were present, where a delayed
rise in viral load above the median load during progression to
disease (10
4.5 copies per ml) was observed in individuals who
were homozygous (QQ) or heterozygous (RQ) for the 136Q
genotype as compared to individuals with the wild type
genotype (RR).
The protective effect of the 136Q Trim5a variant on
disease progression only after the emergence of X4-variants,
may imply that Trim5a in vivo affects replication of X4-
variants more efﬁciently than R5-variants. X4-variants devel-
op in 50% of the HIV-1 infected individuals during the
natural course of infection after which R5- and X4-variants
coexist [35–37]. While co-existing R5- and X4-variants infect
memory CD4 T cells that co-express CCR5 and CXCR4, X4-
variants have the unique ability to additionally infect naive
CD4 T cells that selectively express CXCR4 [35,36]. Here we
observed that naı ¨ve CD4 T cells expressed higher levels of
Trim5a as compared to memory CD4 T cells. It is tempting to
speculate that high Trim5a expression levels in naive T cells
in combination with a more potent antiviral activity
associated with the 136Q polymorphism provide prolonged
control of HIV-1 replication in carriers of X4-variants.
Recently a G to C polymorphism at position  2 in the
59UTR of the Trim5 gene ( 2G/C; rs3824949) in combination
with the R136Q polymorphism has been associated with HIV-
1 susceptibility and disease progression [29]. Speelmon et al.
observed an enrichment of the 136Q/ 2G haplotype in the
HIV-1 positive population [29], however we were unable to
conﬁrm this and observed an equal distribution of the 2G/C
polymorphism in combination with the 136Q allele between
the HIV-1 positive population and the control group.
However, the 136Q allele in combination with the  2GG
genotype was associated with accelerated disease progression
in our study population. Speelmon et al. observed an
association between a faster CD4 T cell decline and the
136R/ 2G haplotype [29], but we were unable to conﬁrm this.
In our study population we observed a  2C allele frequency
of 0.486 and 0.418 in the HIV-1 positive study population and
the control group, respectively, which is similar to the
frequencies in the European American population reported
by Javanbakht et al. [30]. However the frequencies for the 2C
allele frequencies in the study populations of Speelmon et al.
were much lower (0.38 in exposed seronegatives and 0.31 in
HIV-1 infected population) [29]. Therefore, it cannot be
excluded that differences in the distribution of the  2G/C
polymorphism in different study populations account for the
observed discrepancies in results.
Our data conﬁrm a role of Trim5a in the clinical course of
infection. In addition, they show that different genetic
variants in Trim5a are associated with a differential clinical
course of infection. Overall, these results may encourage
exploiting the possibility of using Trim5a or alike derivatives
in antiviral strategies.
Materials and Methods
Study participants. The study population, 364 Caucasian, homo-
sexual men enrolled in the Amsterdam Cohort studies (ACS) on the
Table 3. Univariate and Multivariate Relative Hazards for Progression to AIDS (CDC 1987) for the H43Y Genotype, Presence of X4-
Variants, CD4 T Cell Count, Viral RNA Load in Plasma, or CCR5 Genotype at Two Years after Seroconversion
Progression Marker Crude Adjusted
p-Value RH (95.0% CI) p-Value RH (95.0% CI)
Trim5 43YY genotype 4.2E-03 3.4 (1.5–7.6) 1.4E-02 4.5 (1.4–15.1)
CCR5-D32 genotype 1.2E-05 0.4 (0.2–0.6) ND
a ND
a
X4-variants
b 1.2E-15 8.1 (4.9–13.6) 1.8E-06 5.8 (2.8–12.0)
CD4 cells ,500 cells per ll
b 6.9E-05 1.9 (1.4–2.7) 1.6E-02 1.8 (1.1–2.8)
Viral RNA load .10
4.5 copies per ml
b 7.2E-06 2.6 (1.7–3.9) 2.7E-04 2.7 (1.5–3.7)
aCCR5-D32 genotype was not observed in combination with the Trim5 43YY genotype.
bThe presence of X4-variants, CD4 T cell counts, and the viral RNA load in plasma was determined at 1.5–2 y after seroconversion.
ND, not determined.
doi:10.1371/journal.ppat.0040018.t003
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Trim5 Polymorphisms and HIV-1 Infectionnatural history of HIV-1 infection between October 1984 and March
1986, was previously described [1]. The censor date of our study was
set at the ﬁrst day of effective antiretroviral therapy of the participant.
Of the 364 participants, 131 seroconverted during the study. The
remaining 233 men were positive for HIV-1 antibodies at entry
between October 1984 and April 1985. In previous epidemiological
studies, the time since seroconversion of these prevalent cases has
been estimated based on the incidence of HIV-1 infection amongst
homosexual participants of the Amsterdam Cohort and was on
average 1.5 years before entry into the cohort studies [34]. For analysis,
we combined the 131 participants with documented seroconversion
and 233 seroprevalent participants with an imputed seroconversion
date as one study group, since previous studies have not revealed
differences in AIDS-free survival between the two groups [4].
The ACS has been conducted in accordance with the ethical
principles set out in the declaration of Helsinki and written informed
consent is obtained prior to data collection. The study was approved by
the Amsterdam Medical Center institutional medical ethics committee.
Trim5 genotyping. DNA samples of 327 out of 364 participants of
the Amsterdam Cohort studies were available for Trim5 genotyping.
For analysis of the Trim5 R136Q polymorphism (rs10838525), DNA
samples were ampliﬁed by PCR using Taq DNA polymerase
(Invitrogen) and primer pair Trim5-F (59-ATGGCTTCTGGAATC
CTGGTTAATG-39) and Trim5-R136Q-R (59-CCCGGGTCTCAGGTC
TATCATG-39). The following ampliﬁcation cycles were used: 5min
958C; 35 cycles of 30s 958C, 30s 508C, 90s 728C; 5min 728C.
Subsequently PCR products were puriﬁed and subjected to a
restriction digest with 1U Ava1 (1.5 hour 378C; NEB) and analyzed
on a 1% agarose gel. A PCR product containing an R at position 136
will result in digestion of the PCR product into a 405bp and 121bp
product. A PCR product containing a Q at position 136 will result in
a 526bp (undigested) product. For conformation, 15 samples (5
homozygous 136R, 5 homozygous 136Q and 5 heterozygous 136QR)
have been sequenced with the ABI prism BigDue Terminator kit V1.1
(Applied Biosystems) using primers Trim5-F and Trim5-R136Q-R).
Sequences were analyzed on an ABI 3130XL Genetic Analyzer.
For analysis of the Trim5 H43Y polymorphism (rs3740996), DNA
samples were ampliﬁed by PCR using Taq DNA polymerase
(Invitrogen) and primer pair Trim5-F and Trim5-H43Y-R (59-
GGCTGGTAACTGATCCGGCAC-39). For analysis of the  2GC poly-
morphism (rs3824949), DNA samples were ampliﬁed by PCR using
Taq DNA polymerase (Invitrogen) and primer pair Tr5 2GC (59-
GCAGGGATCTGTGAACAAGAGG-39) and Trim5-H43Y-R. The fol-
lowing ampliﬁcation cycles were used: 5min 958C; 35 cycles of 30s
958C, 30s 558C, 90s 728C; 5min 728C. Subsequently PCR products were
puriﬁed and sequenced with the ABI prism BigDue Terminator kit
V1.1 (Applied Biosystems) using primers Trim5-F and Trim5-H43Y-R
for H43Y and Tr5 2GC and Trim5-H43Y-R for  2GC. Sequences
were analyzed on an ABI 3130XL Genetic Analyzer.
FACS sorting naı ¨ve and memory CD4 T cells. Cryopreserved PBMC
were stained with antibodies against CD4 (tricolor conjugated; Caltag
Laboratories), CD45RO (FITC conjugated; BD Biosciences) and CD27
(phycoerythrin conjugated; Caltag Laboratories), and sorted using a
MoFlo cell sorter (Cytomation Inc.). Cells were sorted in two different
cell populations: naı ¨ve (CD45RO-CD27þ) CD4 T cells and memory
(CD45ROþ) CD4 T cells.
RNA isolation and quantitative PCR. Total RNA was isolated from
naı ¨ve and memory CD4 cells from HIV-1 infected individuals or
healthy donors, using the RNeasy mini kit (Qiagen, Hilden, Germany).
Subsequently, cDNA was prepared using the SuperScripte First-
Strand Synthesis System for RT-PCR (In Vitrogen). Trim5a mRNA
levels were analyzed by SYBR green qPCR using the LightCycler
(Roche). The reaction mix contained 20 mM Tris-HCl (pH 8.4), 50
mM KCl, 3 mM MgCl2, 200 lM dNTP, 250 lg/ml BSA, 500 nM primers,
SYBR green I nucleic acid gel stain 40,0003 diluted in water, and 0.6
U platinum Taq DNA polymerase (In Vitrogen). The following primer
sets were used for detection of Trim5a cDNA: Trim5a -RNA-F 59-
ccaggatagttccttccatac-39 and Trim5a-R 59-agagcttggtgagcacagagtc-39.
Serial dilution of plasmid DNA containing cDNA of Trim5a were
used as a standard curve. To correct for differences in the cDNA
input, levels of b-actin cDNA were analyzed by a SYBR green qPCR
using the following primer set: BA-RNA-F 59-ggcccagtcctctcccaagtc-
cac-39 and BA-RNA-R 59-ggtaagccctggctgcctccacc-39. A serial dilution
of 8E5 cells was used as a standard curve for b-actin. SYBR green
qPCR was performed using the following program on the Light-
Cycler: (1) preincubation and denaturation: 508C for 2 min, 958C for 2
min; (2) ampliﬁcation and quantiﬁcation: 45 cycles of 958C for 5 sec,
558C for 15 sec, 728C for 15 sec; (3) melting curve: 958C for 0 sec, 658C
for 15 min, 958C for 0 sec with a temperature transition rate of 0.18C/
sec. Speciﬁcity of the PCR products measured using the SYBR green
method was conﬁrmed by a melting curve.
Statistical analysis. Kaplan Meier and Cox proportional hazard
analysis were performed to study the relation between the R136Q and
H43Y polymorphisms in the Trim5 gene and disease progression. The
following endpoints were considered for analysis: (1) AIDS according
to the 1987 Centers for Disease Control and Prevention (CDC)
deﬁnition [38]; (2) AIDS according to the 1993 CDC deﬁnition [39]; (3)
CD4 T cell counts below 200 cells/ll blood; (4) viral RNA load above
10
4.5 copies per ml blood plasma; (5) detection of X4-variants by
coculture of patient PBMC and MT2 cells [37]. Fisher’s exact test was
used to analyze an association between the R136Q, H43Y poly-
morphisms and prevalence of X4-variants. Sequential Bonferroni
correction (Simes-Hochberg method) was used to correct for multi-
ple comparisons [40,41].
Univariate and multivariate relative hazards were calculated at 2
years after seroconversion for the H43Y genotype, CCR5 genotype,
presence of X4-variants at 18–30 months after seroconversion, CD4 T
cells at 18–30 months after seroconversion and viral RNA load at 18–
30 months after seroconversion.
Trim5a mRNA levels in naı ¨ve and memory CD4 T cells were
compared using the Students T test.
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